Thursday, May 11, 2017 8:46:20 AM
Hypi, rumour moves is not what we want for PPHM, IMO. We want solid moves based on solid information. No one wants the PPHM stock up if they want to make money on the up movement.
PPHM has REAL value with Avid, Exosomes, Biomarkers, Cancer Treatment and digital imaging all based on PS-Targeting or at least PS technology and of which they hold all PS molecule side (vs PS receptor side) IP. That is NOW more important then before because PS exposed on cells, floating in the blood and more importantly floating in the blood as part of micro vesicles is all covered by that.
For instance PPHM could, if it would fit their strategy, grand licenses to liquid biopsy vendors that have poor results or are expensive to include techniques involving PS to improve on that. They could do it for those tests that they would not want to develop themselves (say smaller cancers).
Those manufacturers could NEVER include additional PS analysis in their products because PPHM holds the IP the covers the concept of measuring PS in micro-vesicles and/or in the blood stream as a separate peace of IP (apart from the PDS binding in the other two patents (incl. Betabodies that binds with one stage less)).
All that is what we want our PPS to drive on. Furthermore, if we are profitable and since we have no depths (creditors) and we have about 500 Mil$ to write down the first 500Mil$ profits against we will very quickly have a decent bank account filled with cash AND will then very probably start paying dividends. That will wheel in a completely different public of investors then those we have now. It will be those going for the solid quarterly income.
So IMMO let MNKD have its fun while PPHM goes for sustained profitability and builds from there.
PPHM has REAL value with Avid, Exosomes, Biomarkers, Cancer Treatment and digital imaging all based on PS-Targeting or at least PS technology and of which they hold all PS molecule side (vs PS receptor side) IP. That is NOW more important then before because PS exposed on cells, floating in the blood and more importantly floating in the blood as part of micro vesicles is all covered by that.
For instance PPHM could, if it would fit their strategy, grand licenses to liquid biopsy vendors that have poor results or are expensive to include techniques involving PS to improve on that. They could do it for those tests that they would not want to develop themselves (say smaller cancers).
Those manufacturers could NEVER include additional PS analysis in their products because PPHM holds the IP the covers the concept of measuring PS in micro-vesicles and/or in the blood stream as a separate peace of IP (apart from the PDS binding in the other two patents (incl. Betabodies that binds with one stage less)).
All that is what we want our PPS to drive on. Furthermore, if we are profitable and since we have no depths (creditors) and we have about 500 Mil$ to write down the first 500Mil$ profits against we will very quickly have a decent bank account filled with cash AND will then very probably start paying dividends. That will wheel in a completely different public of investors then those we have now. It will be those going for the solid quarterly income.
So IMMO let MNKD have its fun while PPHM goes for sustained profitability and builds from there.
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
